Citations

Showing 10 of 108162 citations.

Melatonin Targets Metabolism in Head and Neck Cancer Cells by Regulating Mitochondrial Structure and Function
Guerra‐Librero, Ana , Fernández-Gil, Beatriz I. , Florido, Javier , Martínez-Ruiz, Laura , Rodríguez-Santana, César , Shen, Yingqiang , García‐Verdugo, José Manuel , López‐Rodríguez, Alba , Rusanova, Iryna , Quiñones‐Hinojosa, Alfredo , Acuña-Castroviejo, Darı́o , Marruecos, J., Haro, Tomás de , Escames, Germaine , García-Verdugo, José M , Escames, Germaine

Mayo Clinic

Antioxidants | April 14, 2021 | Volume: 10 | Issue: 4 | Pages: 603

10.3390/antiox10040603 | PMID 33919790 Get It

Metabolic reprogramming, which is characteristic of cancer cells that rapidly adapt to the hypoxic microenvironment and is crucial for tumor growth and metastasis, is recognized as one of the major mechanisms underlying therapeutic resistance. Mitochondria, which are directly involved in metabolic reprogramming, are used to design novel mitochondria-targeted anticancer agents. Despite being targeted by melatonin, the functional role of mitochondria in melatonin’s oncostatic activity remains unclear. In this study, we aim to investigate the role of melatonin in mitochondrial metabolism and its functional consequences in head and neck cancer. We analyzed the effects of melatonin on head and neck squamous cell carcinoma (HNSCC) cell lines (Cal-27 and SCC-9), which were treated with 100, 500, and 1500 µM of melatonin for 1, 3, and 5 days, and found a connection between a change of metabolism following melatonin treatment and its effects on mitochondria. Our results demonstrate that melatonin induces a shift to an aerobic mitochondrial metabolism that is associated with changes in mitochondrial morphology, function, fusion, and fission in HNSCC. We found that melatonin increases oxidative phosphorylation (OXPHOS) and inhibits glycolysis in HNSCC, resulting in increased ROS production, apoptosis, and mitophagy, and decreased cell proliferation. Our findings highlight new molecular pathways involved in melatonin’s oncostatic activity, suggesting that it could act as an adjuvant agent in a potential therapy for cancer patients. We also found that high doses of melatonin, such as those used in this study for its cytotoxic impact on HNSCC cells, might lead to additional effects through melatonin receptors.
The emerging paradigm of calcium homeostasis as a new therapeutic target for protozoan parasites
Gupta, Yash , Goicoechea, Steven , Pearce, Catherine M., Mathur, Raman, Romero, Jesús G., Kwofie, Samuel K., Weyenberg, Matthew C., Daravath, Bharathi, Sharma, Neha , Akala, Hoseah M. , Kanzok, Stefan M. , Durvasula, Ravi , Rathi, Brijesh , Kempaiah, Prakasha , Kempaiah, Prakasha , Rathi, Brijesh , Akala, Hoseah M , Kwofie, Samuel K , Gupta, Yash , Poonam, Poonam

Mayo Clinic

Medicinal Research Reviews | April 14, 2021 | Volume: 42 | Issue: 1 | Pages: 56-82

10.1002/med.21804 | PMID 33851452 Get It

AbstractCalcium channels (CCs), a group of ubiquitously expressed membrane proteins, are involved in many pathophysiological processes of protozoan parasites. Our understanding of CCs in cell signaling, organelle function, cellular homeostasis, and cell cycle control has led to improved insights into their structure and functions. In this article, we discuss CCs characteristics of five major protozoan parasites Plasmodium, Leishmania, Toxoplasma, Trypanosoma, and Cryptosporidium. We provide a comprehensive review of current antiparasitic drugs and the potential of using CCs as new therapeutic targets. Interestingly, previous studies have demonstrated that human CC modulators can kill or sensitize parasites to antiparasitic drugs. Still, none of the parasite CCs, pumps, or transporters has been validated as drug targets. Information for this review draws from extensive data mining of genome sequences, chemical library screenings, and drug design studies. Parasitic resistance to currently approved therapeutics is a serious and emerging threat to both disease control and management efforts. In this article, we suggest that the disruption of calcium homeostasis may be an effective approach to develop new anti‐parasite drug candidates and reduce parasite resistance.
Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
Eißing, Thomas , Stewart, Michael W., Qian, Cynthia X. , Rittenhouse, Kay D.

Mayo Clinic

Translational Vision Science & Technology | April 14, 2021 | Volume: 10 | Issue: 4 | Pages: 9

10.1167/tvst.10.4.9 | PMID 34003985 Get It

The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin
Flamm, Steven L., Brown, Kimberly , Wadei, Hani M. , Kugelmas, Marcelo , Samaniego, Milagros , Burra, Patrizia , Poordad, Fred , Saab, Sammy , Wadei, Hani M , Brown, Robert S. , Samaniego-Picota, Milagros

Mayo Clinic

Liver Transplantation | April 14, 2021 | Volume: 27 | Issue: 8 | Pages: 1191-1202

10.1002/lt.26072 | PMID 33848394 Get It

Acute kidney injury (AKI) in the setting of cirrhosis (hepatorenal syndrome [HRS]–AKI) is a severe and often fatal complication of end‐stage liver disease. The goals of treatment are to reverse renal failure and prolong survival in patients who are critically ill. However, interventions have limited efficacy, and mortality rates remain high. In the United States, the mainstay of pharmacologic therapy consists of the off‐label use of vasoconstrictive agents in combination with plasma expanders, a strategy that produces modest effects. Liver transplantation is the ultimate solution but is only an option in a minority of patients because contraindications to transplantation are common and organ availability is limited. Renal replacement therapy is a temporary option but is known to confer an extremely poor short‐term prognosis in patients with HRS‐AKI and at best serves as a bridge to liver transplantation for the minority of patients who are transplantation candidates. The high mortality rate associated with HRS‐AKI in the United States is a reflection of the suboptimal standard of care. Improved therapeutic options to treat HRS‐AKI are sought. Terlipressin is a drug approved in Europe for treatment of HRS‐AKI and supported by recommendations for first‐line therapy by some liver societies and experts around the world. This review article will discuss the substantial unmet medical need associated with HRS‐AKI and the potential benefits if terlipressin was approved in the United States.
Clinical efficacy and safety of magnetic sphincter augmentation (MSA) and transoral incisionless fundoplication (TIF2) in refractory gastroesophageal reflux disease (GERD): a systematic review and meta-analysis
Khan, Shahab R. , Jha, Lokesh K. , Dhaliwal, Amaninder J., Aziz, Muhammad , Arora, Sumant, Malik, Sarah , Kassab, Lena L., Ponnada, Suresh, Bhat, Ishfaq , Hewlett, Alexander , McDonough, Stephanie, Chandan, Saurabh , Mohan, Babu P. , Bilal, Mohammad , Canakis, Andrew , Sharma, Neil, Adler, Douglas G.

Mayo Clinic

Endoscopy International Open | April 14, 2021 | Volume: 09 | Issue: 04 | Pages: E583-E598

10.1055/a-1352-2944 | PMID 33869732 Get It

Abstract Background and study aims Proton pump inhibitors (PPI) are effective medical therapy options for gastro-esophageal reflux disease (GERD). However, 20 % to 40 % of patients report symptoms despite taking daily PPI. Transoral incisionless fundoplication (TIF2) and magnetic sphincter augmentation (MSA) are less invasive options for the treatment of refractory GERD and are increasingly gaining popularity. Methods We conducted a comprehensive search of several databases to identify relevant studies. Our primary aim was to compare the efficacy of both interventions reported as improvement in Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) score, overall patient satisfaction, improvement in post-procedure regurgitation, and fraction of patients completely off PPI therapy at follow up. Results Twenty-four studies with 1942 patients were included in the final analysis. Both MSA and TIF2 had comparable technical success and clinical success based on improvement in GERD-HRQL scores i. e. 98.8 % (CI 95.6,99.7) vs 98.5 % (CI 95.7,99.5) and 80.4 % (CI 66,89.6) vs 77.7 % (CI 64.1,87.2), respectively. A significantly greater proportion of patients reported improvement in regurgitation, i. e. 91.1 % (CI 83.8,95.3) vs 73.1 % (CI 62.5,81.7) and were able to completely discontinue PPI therapy with MSA compared to TIF2 i. e. 91.3 % (CI 81.5,96.2) vs 63.8 % (CI 51.6,74.4). Patients’ BMI and presence of a hiatal hernia did not have any effect on procedural outcomes. Conclusion Both procedures performed at par when comparing clinical success in terms of improvement in GERD-HRQL scores. In terms of overall patient satisfaction, post procedure regurgitation and cumulative number of patients off PPI therapy, MSA outperforms TIF2.
Neurological Complications in Patients with Heart Transplantation
Sakusic, Amra , Rabinstein, Alejandro A.

Mayo Clinic

Seminars in Neurology | April 14, 2021 | Volume: 41 | Issue: 04 | Pages: 447-452

10.1055/s-0041-1726285 | PMID 33851398 Get It

AbstractNeurological complications after heart transplantation are common and include cerebrovascular events (ischemic strokes, hemorrhagic strokes, and transient ischemic attacks), seizures, encephalopathy, central nervous system (CNS) infections, malignancies, and peripheral nervous system complications. Although most neurological complications are transient, strokes and CNS infections can result in high mortality and morbidity. Early recognition and timely management of these serious complications are crucial to improve survival and recovery. Diagnosing CNS infections can be challenging because their clinical presentation can be subtle in the setting of immunosuppression. Immunosuppressive medications themselves can cause a broad spectrum of neurological complications including seizures and posterior reversible encephalopathy syndrome. This article provides a review of the diagnosis and management of neurological complications after cardiac transplantation.
MRI Study of Jellyfish Collagen, Hyaluronic Acid, and Cadaveric Dermis for Injection Laryngoplasty
San‐Marina, Serban , Oldenburg, Michael , Voss, Stephen G. , Hunter, Danielle E., Meloche, Ryan , Miller, Alen Lee, Spragg, Andrew Mearns, Ekbom, Dale C. , Oldenburg, Michael S , Voss, Stephen , Macura, Slobodan , Ekbom, Dale , Bowen, Andrew J.

Mayo Clinic

The Laryngoscope | April 14, 2021 | Volume: 131 | Issue: 8 | Pages: No page available

10.1002/lary.29501 | PMID 33847388 Get It

AbstractObjectives/HypothesisTest a new jellyfish collagen biomaterial aimed to increase duration of injection medialization laryngoplasty (IL) against two products in clinical practice.Study DesignAnimal model.MethodsLeft recurrent laryngeal nerve sectioning and IL were performed in New Zealand White rabbits (N = 6/group). Group 1 received micronized cross‐linked jellyfish collagen (MX‐JC) and adipose derived stem cells (ADSCs), Group 2, MX‐JC alone, Group 3, cross‐linked hyaluronic acid (X‐HA), and Group 4, micronized acellular dermis (MACD). Animals were sacrificed at 4 and 12 weeks. Major outcomes were MRI tissue volumes and histopathology.ResultsAfter 100 μL IL MRI volumes (means ± STD) at 4 and 12 weeks were: Group 1: 27.2 ± 15.6 and 13.1 ± 5.2 μL, Group 2: 60.8 ± 18 and 27.8 ± 2.47 μL, Group 3: 27.4 ± 12 and 10.6 ± 8 μL, and Group 4: 37.5 ± 11 and 9.85 ± 1 μL. Group 2 volumes were largest and Group 3 were smallest in all comparisons (P < .05). Histologically, low grade inflammatory responses were observed in Group 1, mild histiocytic infiltration in Group 2, widespread muscle fiber loss in Group 3, and plasmocytic infiltration in Group 4.ConclusionsMX‐JC showed the least resorption at 4 and 12 weeks among all groups. T cell inflammatory responses were observed with MX‐JC but were reduced by 12 weeks while B cell immune responses, indicative of antibody priming, were predominantly noted with MACD. MX‐JC + ADSC showed low grade immunity while the XHA showed greater myocyte loss compared to the other groups.Level of EvidenceNA Laryngoscope, 131:E2452–E2460, 2021